Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

Tempus AI

Status: Enrolling

Conditions: Colorectal Cancer

Treatments: Other: Observation

Study type: Observational

Funder types: Industry

Identifiers

NCT05234177

TP-CA-004

Details and patient eligibility

About

The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Known or suspected colorectal adenocarcinoma (Stage I to IVA disease)
• Planning to undergo or has undergone a surgical resection for suspected adenocarcinoma of the colon or rectum with curative intent.
• 18 years old or older
• Willing and able to provide informed consent
• Willing to have additional blood samples collected during routine surveillance visits

Exclusion criteria

• Not willing to have additional blood samples collected
• Pathology that is not consistent with colorectal adenocarcinoma

Trial design

300 participants in 1 patient group

Participants with stage I-IV colorectal cancer (CRC)

Description:

This protocol will include participants with stage I-IV CRC who are scheduled to undergo or have undergone a surgical resection with curative intent.

Treatment:

Other: Observation